Abstract
Silencing RNA (siRNA) are generally about 20–22 nucleotides long that are known to significantly enhance the delivery of RNA drugs and its therapeutic approach are mostly concentrated on cancer treatment, where the siRNA is doped with anti-cancer drug for delivery to the metastatic site that are known to restrain the oncogenes such as c-Myc, K-Ras, Wnt, and also variations in the nucleotide sequence of tumor suppressor genes such as p53, APC, etc. which regulates the cellular pathways in tumor progression leading to personalized medicine. In-vivo siRNA administration is hindered by low cellular uptake, unstable under physiological conditions, immunogenicity, as well as off target site. Along with the ligand conjugated siRNA, the development of nanotechnology-based siRNA drug delivery system is the most recent approaches to treat cancer. Consequently, the forthcoming criteria of RNA-based drug will need some biochemical alteration that will increase the pharmacokinetic activities and reduce the toxicity level for clinically safe drug delivery system.
This is a preview of subscription content, log in via an institution to check access.
Reference
Bernstein E, Caudy AA, Hammond SM, Hannon GJ (2001) Role for a bidentateribonuclease in the initiation step of RNA interference. Nature 409:363–366
Cogoni C, Macino G (1999) Gene silencing in Neurosporacrassa requires a protein homologus to RNA-depednet RNA polymerase. Nature 399:166–169
Czauderna F, Fechtner M, Dames S et al (2003) Structural variations and stabilizing modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res 31:2705–2716
Davidson BL, McCray PB (2011) Current prospects for RNA interference-based therapies. Nat Rev Genet 12:329–340
Dogini DB, Pascoal VDAB, Avansini SH, Vieira AS, Pereira TC, Lopes-Cendes I (2014) The new world of RNAs. Genet Mol Biol 37:285–293
Dykxhoorn DM, Novina CD, Sharp PA (2003) Killing the messenger: short RNAs that silence gene expression. Nat Rev Mol Cell Biol 4:457–467
Elbashir SM et al (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411:494–498
Elouahabi A, Ruysshaert JM (2005) Formulation and intracellular trafficking of lipoplexes and polyplexes. Mol Ther 11:336–347
Hall AHS, Wan J, Shaughnessy EE et al (2004) RNA interference using boranophosphatesiRNAs: structure-activity relationships. Nucleic Acids Res 32:5991–6000
Hamilton AJ, Baulcombe DC (1999) A species of small antisense RNA in posttranscriptional gene silencing in plants. Science 286:950–952
Hammond SM (2005) Dicing and slicing. The core machinery of the RNA interference pathway. FEBS Lett 579:5822–5829
Jagannath A, Wood M (2007) RNA interference based gene therapy for neurological disease. Brief Funct Genomics 6(1):40–49
Li L, Shen Y (2009) Overcoming obstacles to develop effective and safe siRNA therapeutics. Expert Opin Biol Ther 9:609–619
Liao H, Wang JH (2005) Biomembrane-permeable and ribonucleaseresistant siRNA with enhanced activity. Oligonucleotides 15:196–205
Meister G, Tuschl T (2004) Mechanisms of gene silencing by double-stranded RNA. Nature 431:343–349
Mello CC, Conte D Jr (2004) Revealing the world of RNA interference. Nature 431:338–342
Meng P et al (2015) New paradigms on siRNA local application. BMB Rep 48(3):147–152
Mizuno T, Chou M-Y, Inouye M (1984) A unique mechanism regulating gene expression: translational inhibition by a complementary RNA transcript (miRNA). Proc Natl Acad Sci 81:1966–1970
Parrish S, Fleenor J, Xu S, Mello C, Fire A (2000) Functional anatomy of a dsRNA trigger: differential requirements for the two trigger strands in RNA interference. Mol Cell 6:1077–1087
Samantha MS et al (2015) Technologies for Controlled, local delivery of siRNA. J Control Release 218:94–113
Singh A et al (2017) Advances in siRNA delivery in cancer therapy. Artif Cells Nanomed Biotechnol 46(2):274–283
Singh A et al (2018) Advances in siRNA delivery in cancer therapy. Artif Cells Nanomed Biotechnol 46(2):274–283
Tatiparti K et al (2017) siRNA delivery strategies: a comprehensive review of recent development. Nano 7:77
Wang J et al (2010) Delivery of siRNA therapeutics: barriers and carriers. AAPS J 4:12
Waterhouse PM, Graham MW, Wang M-B (1998) Virusa resistance and gene silencing in plats can be induced by simultaneous expression of sense and antisense RNA. Proc Natl Acad Sci 95:13959–13964
Young SWS, Stenzel M, Yang JL (2016) Nanoparticle-siRNA: a potential cancer therapy? Crit Rev Oncol Hematol 98:159–169
Acknowledgment
This study was supported by a grant from Department of Science and Technology (DST) – Science and Engineering Research Board (SERB) (EMR/2017/001877).
Author Contribution
Surajit Pathak conceived the idea of the article. Antara Banerjee and Janani Gopi, Surajit Pathak, and Francesco Marotta, Secunda Rupert and Rossy Vanilla had written the manuscript. All the authors read and approved the final version of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Singapore Pte Ltd.
About this entry
Cite this entry
Banerjee, A., Gopi, J., Marotta, F., Rupert, S., Vennila, R., Pathak, S. (2021). Importance of Silencing RNAs in Cancer Research. In: Chakraborti, S., Ray, B.K., Roychowdhury, S. (eds) Handbook of Oxidative Stress in Cancer: Mechanistic Aspects. Springer, Singapore. https://doi.org/10.1007/978-981-15-4501-6_100-1
Download citation
DOI: https://doi.org/10.1007/978-981-15-4501-6_100-1
Received:
Accepted:
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-15-4501-6
Online ISBN: 978-981-15-4501-6
eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences